Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
SAR302503 (TG101348) is a potent small molecule inhibitor of Janus kinase 2 (JAK2). This is an extension study for a first-in-man, dose escalation study (MF-TG101348-001). The safety, tolerability and clinical activity of SAR302503 (TG101348) in subjects with myelofibrosis will be evaluated.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Completion of MF-TG101348-001 study
Diagnosis of myelofibrosis
At least 18 years of age
You may not be if
Any acute or chronic medical abnormality that may increase the risk associated with study participation
